Involvement of OCTN2 and B0,+ in the transport of carnitine through an in vitro model of the blood-brain barrier

被引:29
|
作者
Berezowski, V
Miecz, D
Marszalek, M
Bröer, A
Bröer, S
Cecchelli, R
Nalecz, KA
机构
[1] M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland
[2] Univ Artois, Inst Pasteur Lille, Fac Sci Jean Perrin, Lab Mixte,EA 2465, Lens, France
[3] Australian Natl Univ, Fac Sci, Div Biochem & Mol Biol, Canberra, ACT, Australia
关键词
B-0; B-+; transporter; blood-brain barrier; carnitine; OCTN2;
D O I
10.1111/j.1471-4159.2004.02752.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Carnitine is known to accumulate in brain, therefore transport of carnitine through the blood-brain barrier was studied in an in vitro system using bovine brain capillary endothelial cells (BBCEC) grown on filter inserts in a co-culture system with glial cells. Long-term exposure of BBCEC to carnitine resulted in a high accumulation of long-chain acyl carnitines, which decreased dramatically upon removal of carnitine. Kinetic analysis of carnitine accumulation indicated a possibility of functioning of more than one transporter. BBCEC were incubated in the presence of substrates and inhibitors of known carnitine transporters added from either apical or basolateral side. Inhibition by replacement of sodium and expression of OCTN2 (RT-PCR) were in agreement with earlier reports on the functioning of OCTN2 in apical membrane. For the first time, functioning of OCTN2 was demonstrated in the basolateral membrane, as well as functioning in both membranes of a low affinity carnitine transporter B-0,B-+. Expression of B-0,B-+ in BBCEC was confirmed by RT-PCR. These results suggest that OCTN2 and B-0,B-+ could be involved in carnitine transport in both the apical and basolateral membrane.
引用
收藏
页码:860 / 872
页数:13
相关论文
共 50 条
  • [21] The in vitro blood-brain barrier: the assessment of drug transport to the brain
    Dehouck, MP
    Fenart, L
    Dehouck, B
    Cecchelli, R
    ANIMAL ALTERNATIVES, WELFARE, AND ETHICS, 1997, 27 : 869 - 872
  • [22] Quantitative analysis of nanoparticle transport through in vitro blood-brain barrier models
    Aberg, Christoffer
    TISSUE BARRIERS, 2016, 4 (01):
  • [23] A dynamic model of the blood-brain barrier ''in vitro''
    Stanness, KA
    Guatteo, E
    Janigro, D
    NEUROTOXICOLOGY, 1996, 17 (02) : 481 - 496
  • [24] Transport of Arylsulfatase A across the Blood-Brain Barrier in Vitro
    Matthes, Frank
    Woelte, Philipp
    Boeckenhoff, Annika
    Huewel, Sabine
    Schulz, Mareike
    Hyden, Pia
    Fogh, Jens
    Gieselmann, Volkmar
    Galla, Hans-Joachim
    Matzner, Ulrich
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (20) : 17487 - 17494
  • [25] Transport of amentoflavone across the blood-brain barrier in vitro
    Gutmann, H
    Bruggisser, R
    Schaffner, W
    Bogman, K
    Botomino, A
    Drewe, J
    PLANTA MEDICA, 2002, 68 (09) : 804 - 807
  • [26] Advances of Blood-brain Barrier Model In Vitro
    Lin Lan
    Sun De-Qun
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2019, 46 (10) : 966 - 975
  • [27] A useful in vitro blood-brain barrier model
    Hurst, RD
    NEUROREPORT, 2000, 11 (07) : L1 - L2
  • [28] Functional Expression of Organic Cation/carnitine Transporter 2 (OCTN2/SLC22A5) in Human Brain Capillary Endothelial Cell Line hCMEC/D3, a Human Blood-brain Barrier Model
    Okura, Takashi
    Kato, Sayaka
    Deguchi, Yoshiharu
    DRUG METABOLISM AND PHARMACOKINETICS, 2014, 29 (01) : 69 - 74
  • [29] Transport of treosulfan and temozolomide across an in-vitro blood-brain barrier model
    Linz, Ute
    Hupert, Michelle
    Santiago-Schuebel, Beatrix
    Wien, Sascha
    Stab, Julia
    Wagner, Sylvia
    ANTI-CANCER DRUGS, 2015, 26 (07) : 728 - 736
  • [30] Copper Transport Mediated by Nanocarrier Systems in a Blood-Brain Barrier In Vitro Model
    Fehse, Susanne
    Nowag, Sabrina
    Quadir, Mohiuddin
    Kim, Kwang Sik
    Haag, Rainer
    Multhaup, Gerd
    BIOMACROMOLECULES, 2014, 15 (05) : 1910 - 1919